Drugs for the control of parasitic diseases: current status and development in schistosomiasis

Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia

“…The mean age of the study population was 11.4 (age range: 6 to 22 years) with the highest proportion of individuals lying in the [10][11][12][13][14] Most of the S. mansoni infected children were either cured or the intensity of infection became significantly reduced.…”

“…However, praziquantel (PZQ) remains the drug of choice in the treatment of schistosomiasis since the 1970s [10][11][12] . Nevertheless, few recent reports on low cure rate of praziquantel have raised some concern about its current Objective: To evaluate the efficacy and side effects of praziquantel (PZQ) in the treatment of schistosomiasis in Ethiopia.…”

Schistosomes—proteomics studies for potential novel vaccines and drug targets

“…Praziquantel is effective against all Schistosoma species infecting humans, has been extensively tested, does not display severe side effects and is currently inexpensive and available [4,5].…”

Morbidity due to Schistosoma mansoni: an epidemiological assessment of distended abdomen syndrome in Ugandan school children with observations before and 1-year after anthelminthic chemotherapy

“…Since control of schistosomiasis in high burden areas is primarily concerned with morbidity reduction through the use of regular anthelminthic chemotherapy (Fenwick et al, 2003;Utzinger and Keiser, 2004;WHO, 2002WHO, , 2004, interest has increased in better describing the public health burdens of schistosomiasis both at national and local levels (van der Werf et al, 2002(van der Werf et al, , 2003, as well as clearly demonstrating morbidity reversion post treatment (Boisier et al, 1998;Brooker et al, 2004;Lambertucci et al, 2000).…”